MedTrace Logo

Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies

NCT07240805 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-04-09

No results posted yet for this study

Summary

Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily function. Researchers at BioSensics, Johns Hopkins School of Medicine, Massachusetts General Hospital and their collaborators aim to conduct an analytical and clinical validation of wearable-based digital health technologies for monitoring upper and lower limb function in PSP, MCI-LB and DLB that could enable frequent, at-home monitoring and be incorporated into future clinical trials.

Conditions

  • Progressive Supranuclear Palsy(PSP)
  • Dementia With Lewy Bodies (DLB)
  • PSP
  • Lewy Body Dementia (LBD)
  • Lewy Body Disease

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Johns Hopkins University

    collaborator OTHER

  • Massachusetts General Hospital

    collaborator OTHER

  • BioSensics

    lead INDUSTRY

Eligibility

Min Age
40 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-15
Primary Completion
2028-07-01
Completion
2029-01-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07240805 on ClinicalTrials.gov